메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국임상약학회 한국임상약학회지 한국임상약학회지 제22권 제1호
발행연도
2012.1
수록면
81 - 86 (6page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
This study was aimed to examine the prescribing patterns of antivirals in chronic hepatitis B(CHB)for outpatients. National Health Insurance adjudicated claims data(total 1,426,065 claims) dated March 19, 2008 submitted from nationwide healthcare providers to Health Insurance Review and Assessment Service were used in this study. 2,965 claims included CHB diagnosis(ICD-10 code B18.0 and B18.1). 44.2%(1,311) of CHD related claims included antiviral prescription such as lamivudine, clevudine, adefovir and entecavir which were currently available. Lamivudine, adefovir,clevudine and entecavir shared 54.9%, 19.9%, 13.2% and 11.9%, respectively among antiviral prescriptions. Adefovir and entecavir 1mg presumed as the 2nd line therapy for HBV resistant cases were shared 23.3% of overall antiviral prescriptions. There were statistically significant difference in prescription patterns according to age and instititution type: Lamivudine usage was higher in younger(< 20) and older age group(> 70 year old) than others(p = 0.016), and adefovir and entecavir which were relatively newer antivirals had higher prescription rate in higher level of institutions such as the 3rd level hospital than others(p < 0.001). This study would be of help to makeappropriate drug therapy plan for CHB patients.

목차

등록된 정보가 없습니다.

참고문헌 (14)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0